Brokerages expect Acorda Therapeutics Inc (NASDAQ:ACOR) to post ($0.77) earnings per share (EPS) for the current quarter, according to Zacks. Six analysts have made estimates for Acorda Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.81) and the highest estimate coming in at ($0.71). Acorda Therapeutics reported earnings of $0.17 per share during the same quarter last year, which indicates a negative year over year growth rate of 552.9%. The company is expected to issue its next quarterly earnings report on Wednesday, October 30th.
According to Zacks, analysts expect that Acorda Therapeutics will report full-year earnings of ($2.74) per share for the current year, with EPS estimates ranging from ($2.94) to ($2.55). For the next year, analysts expect that the company will report earnings of ($3.42) per share, with EPS estimates ranging from ($5.21) to ($2.66). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.53. Acorda Therapeutics had a negative return on equity of 6.18% and a negative net margin of 25.94%. The business had revenue of $50.05 million for the quarter, compared to the consensus estimate of $28.83 million. During the same period in the prior year, the business earned $1.40 EPS. The firm’s revenue for the quarter was down 67.4% on a year-over-year basis.
ACOR stock traded down $0.06 during trading on Friday, reaching $3.12. 1,111,475 shares of the stock were exchanged, compared to its average volume of 2,187,457. The firm’s 50 day moving average is $5.14 and its 200 day moving average is $10.00. Acorda Therapeutics has a twelve month low of $2.27 and a twelve month high of $29.75. The company has a current ratio of 3.81, a quick ratio of 3.52 and a debt-to-equity ratio of 0.69. The firm has a market cap of $152.98 million, a P/E ratio of 1.71 and a beta of 1.11.
Institutional investors have recently modified their holdings of the company. KBC Group NV purchased a new stake in shares of Acorda Therapeutics in the second quarter worth approximately $31,000. Oppenheimer Asset Management Inc. raised its stake in shares of Acorda Therapeutics by 45.8% in the first quarter. Oppenheimer Asset Management Inc. now owns 4,106 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 1,289 shares during the last quarter. Piedmont Investment Advisors Inc. purchased a new stake in shares of Acorda Therapeutics in the first quarter worth approximately $134,000. BNP Paribas Arbitrage SA raised its stake in shares of Acorda Therapeutics by 869.8% in the first quarter. BNP Paribas Arbitrage SA now owns 10,241 shares of the biopharmaceutical company’s stock worth $136,000 after purchasing an additional 9,185 shares during the last quarter. Finally, Gabelli Funds LLC purchased a new stake in shares of Acorda Therapeutics during the second quarter valued at approximately $80,000.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Featured Article: Average Daily Trade Volume – What It Means In Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.